Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Friday, Benzinga reports. The firm currently has a $50.00 price objective on the stock.

A number of other brokerages also recently weighed in on GMAB. BTIG Research increased their price target on Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a report on Thursday, June 27th. JPMorgan Chase & Co. reiterated a neutral rating on shares of Genmab A/S in a report on Tuesday, August 20th. Royal Bank of Canada raised shares of Genmab A/S from a sector perform rating to an outperform rating in a research report on Monday, July 15th. Morgan Stanley reissued an equal weight rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, Truist Financial cut their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a buy rating on the stock in a research report on Monday, September 9th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Genmab A/S currently has an average rating of Hold and an average price target of $45.20.

Genmab A/S Trading Up 1.5 %

Shares of Genmab A/S stock opened at $26.90 on Friday. The business has a 50-day moving average price of $27.25 and a two-hundred day moving average price of $28.06. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $38.80. The company has a market cap of $17.79 billion, a P/E ratio of 22.42, a PEG ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. Equities research analysts forecast that Genmab A/S will post 1.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. Russell Investments Group Ltd. lifted its position in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after acquiring an additional 544 shares in the last quarter. GAMMA Investing LLC lifted its position in Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after acquiring an additional 749 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Genmab A/S in the 1st quarter valued at about $43,000. Principal Securities Inc. bought a new position in Genmab A/S in the 4th quarter valued at about $77,000. Finally, Barometer Capital Management Inc. bought a new position in Genmab A/S in the 4th quarter valued at about $121,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.